Business Wire

56th Annual Symposium of the SSIEM: APR Will Introduce Its Innovative Phe-Free Medical Food for PKU Management Together with New Original Scientific Data

Del

APR Applied Pharma Research sa (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, is proud to announce it will take part to the forthcoming Annual Symposium of the SSIEM (Society for the Study of Inborn Errors of Metabolism), which will be held in Athens on September 4th-7th.

This international congress, attended by academic leaders, clinicians and research scientists from leading Universities and Institutes, will be the showcase for presenting officially the company innovative Phenylalanine (Phe)-free medical food for Phenylketonuria (PKU) dietary management, powered by APR patented Physiomimic™ Technology.

In the occasion of the congress, APR will sponsor the satellite symposium “Physiological Absorption of amino acids: rationale and expected benefits” (Thursday 6th Sept from 7.30 to 8.30 am – Mitropoulos Hall), where international experts in PKU will share and discuss the projected benefits for PKU patients of a medical food providing a prolonged release of amino acids (AA) allowing an efficient utilization of AAs.

The Satellite Symposium, chaired by Prof. Francjan Van Spronsen and Prof. Alberto Burlina and involving Prof. Rani Singh, Dr. Julio César Rocha, Prof. Anita Mac Donald, will offer the opportunity to learn about the distinctive features of APR Phe-free medical food for PKU management and the patented technology behind it – Phyisiomimic™ Technology, whilst being introduced to scientific data (preclinical and kinetics in human subjects) underpinning the company innovation.

In addition, during the congress, new pre-clinical data supporting the potential of APR’s innovative AA formulation to modulate the trend of some metabolic markers in the same direction as dietary proteins (“Preliminary indications of metabolic modulation by provision of amino acids engineered to allow physiological absorption”) will be presented in a poster.

As confirmed by a recent international market research, management of PKU still represents a challenge for clinicians, patients and families who depend to varying degrees on a restricted long-life dietary regimen and AA supplementations. Innovative solutions that improve the efficiency of AA utilization and control better the Phe levels fluctuations, while maintaining normal energy intake, are a real existing need.

APR Phe-free Medical Food, powered by the patented Physiomimic™ Technology, has been specifically engineered to allow a physiological absorption of amino acids, mimicking that of dietary proteins. Its advanced formulation has the potential to contribute to the maintenance of PHE levels within the recommended ranges, with less prominent fluctuations of PHE levels over time, thus meeting one of the most significant healthcare professionals’ concerns. The applied patented technology, on the other hand, is able to mask taste and odor of free amino acids, by creating a product that can be easily accepted by patients in order to obtain a better and lasting compliance to the dietary treatment.

We are extremely pleased to have the honor to take part to this important event and to offer to patients and healthcare professionals a new option for PKU management, which marks an important milestone for our company: being a player in the inherited metabolic diseases arena. said Giorgio Reiner, Corporate Director R&D of APR ”Starting from PKU unmet clinical and nutritional needs, we leveraged our extensive know-how in pharmaceutical technologies to develop a Medical Food which aims at delivering significant and tangible benefits for a better quality of life.”

Throughout the lifetime of the event, APR will be available at its booth in the Exhibition Area, where it will be possible to get to know the company innovation, gather information and interview the company staff.

About Phenylketonuria or PKU

Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“Phe”), an essential amino acid found in most protein-containing food. Excessive amounts of Phe in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-Phe) dietetic treatment combined with a daily assumption of low-protein modified foods and medical food, which provides Phe-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.

About APR Applied Pharma Research s.a.

APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.

For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharmaproducts/medical-prescription/genetic-metabolic-disease/

Contact information

APR Applied Pharma Research s.a.:
Paolo Galfetti, +41 91 6957020
Chief Executive Officer
paolo.galfetti@apr.ch

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Project Management Institute Launches New Reports on Navigating the New Normal of Disruptive Technologies During Seventh Annual PMO Symposium®12.11.2018 16:43Pressemelding

Project Management Institute (PMI) today unveiled three thought leadership reports focused on navigating the new normal of disruptive technologies. The new reports were released during the organization’s seventh annual PMO Symposium® in Washington D.C., where more than 650 of the world’s top project management office (PMO) executives, organizational leaders and senior decision makers have gathered to discuss how disruptive technologies—such as cloud solutions, internet of things (IoT) and artificial intelligence (AI)—have changed the way organizations do business and transformed entire industries. Throughout 2018, PMI and partners, have been exploring disruptive technologies and how organizations are using them to achieve their goals in these changing times. While no one single factor can drive benefits realization, leading organizations understand that proven project management practices lead to greater success and less waste. Produced in partnership with Accenture, PMI’s report — For

Separate Independent Studies Found that PREVENA™ Therapy Reduced Complications Following Breast Cancer Surgery and Breast Reconstruction12.11.2018 14:00Pressemelding

KCI, an Acelity Company, announced today that recently published data stemming from two studies demonstrate that closed incision negative pressure therapy (ciNPT) with the PREVENA™ Incision Management System reduced postsurgical wound complication potential in patients recovering from oncological breast surgery and breast reconstruction, respectively. One study titled, “The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes,” showed that patients who received ciNPT with the PREVENA™ System had significantly lower rates of overall complications and returns to the operating room compared to those in the standard of care (SOC) for incision management after breast reconstruction post-mastectomy group. In addition, patients in the PREVENA™ Therapy group overall had a shorter mean time to complete removal of all drains than the SOC group, averaging 9.9 days versus 13.1, respectively.1 In a separate study titled, “Closed Incision Negative Press

Itron Invites Innovators to Participate in Smart City Challenge12.11.2018 13:45Pressemelding

Itron, Inc. (NASDAQ: ITRI) is calling for hardware and software vendors to submit their products and solutions to the inaugural Itron Smart City Challenge. IoT solution providers will compete for the chance to work with leading smart cities, including Glasgow and the City of London, to deploy breakthrough solutions. Applications are due by Jan. 4, 2019. Participants are invited to develop solutions to address challenges defined by the participating cities. Glasgow: Improve travel choices and experience during events in the city while promoting the overall city center offer The City of Glasgow is one of the world’s top sporting cities and a major destination for conferences and concerts. Many thousands of people come to the city on a regular basis to experience its year-round calendar of events. However, this brings significant challenges in getting people safely and conveniently around the city to their location. It also impacts residents and particularly, the public transport system.

US-Based Lineage Logistics Acquires UK Cold Storage, Frozen Food and Logistics Service Provider Yearsley Group12.11.2018 12:00Pressemelding

Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s most innovative and trusted provider of temperature-controlled supply chain solutions, today announced it has acquired Yearsley Group Limited (“Yearsley”), a leading temperature-controlled logistics service provider and frozen food distributor in the UK. Financial terms of the transaction were not disclosed. “Yearsley has demonstrated a strong commitment to developing longstanding, bespoke customer relationships that is consistent with how we do business at Lineage. Bringing Yearsley into the Lineage family enables us to better serve customers in the UK market and further reinforces our international logistics capabilities,” said Greg Lehmkuhl, President and Chief Executive Officer of Lineage Logistics. “Our acquisition by Lineage is a tremendous opportunity for Yearsley customers and employees alike,” said Jonathan Baker, Chief Executive of Yearsley Group. “Lineage’s commitment to innovation and service is unmat

B2BX Cryptocurrency Exchange Secures Full Regulatory Approval in Estonia12.11.2018 09:29Pressemelding

B2BX Exchange, a leading professional digital asset trading platform, announced today that it has received approval for a regulatory licence from the Estonian Financial Intelligence Unit (FIU). The licence means that B2BX will be able to operate as a completely regulated exchange for trading cryptocurrencies and makes it one of the first exchanges in Europe to secure this form of recognition. B2BX Exchange, part of the B2Broker group of companies, applied for its licence in Estonia due to the country’s reputation for being highly innovative and technology-friendly. Furthermore, the EU-member country continues to take a leading stance in the advancement of blockchain technologies and cryptocurrency regulation. The licence, which comes into effect shortly, will open the door for B2BX Exchange to provide an extended level of services which currently includes a crypto-to-crypto service and soon to be crypto-to-fiat, as well as providing peace of mind for B2BX Exchange users by way of incre

GSMA Elects New Board Members and Announces Orange Chairman and CEO Stéphane Richard as Chair12.11.2018 09:00Pressemelding

The GSMA today announced that it has elected new members of the GSMA Board for the two-year period from January 2019 through December 2020. The GSMA Board has also elected Stéphane Richard, Chairman and Chief Executive Officer of Orange Group as Chair, and Chua Sock Koong, Group Chief Executive Officer of Singtel Group as Deputy Chair. As GSMA Chair, Richard will oversee the strategic direction of the organisation, which represents more than 750 of the world’s mobile operators, as well as over 350 companies in the broader mobile ecosystem. “I am honoured to be elected to serve as Chair of the GSMA and look forward to working closely with the rest of the Board, the GSMA leadership team and our entire membership to address the critical issues facing our industry and our customers,” said Stéphane Richard, Chairman and Chief Executive Officer of Orange. “Mobile operators and our wider industry have a key role to play in promoting a safer and more inclusive digital world, while building the